Sanpower and Dendreon: the New Beginning
Date: April 22, 2018 @ 2:00 pm – @ 5:00 pm
Location: Stanford University 1265 Welch Road, 3rd Floor Palo Alto, CA 94305
Sanpower and Dendreon: the New Beginning
Date and Time
Sun, April 22, 2018
2:00 PM – 5:00 PM PDT
Location
Stanford University
1265 Welch Road, 3rd Floor
Palo Alto, CA 94305
Seats are limited, Registration is free but encouraged
The event is organized by CABS
In 2017, Sanpower Group, one of the largest private conglomerates in China, made the biggest spash at JP Morgan Healthcare Investors Conference, announcing the completion of Dendreon from Valeant for $820 million. Dendreon's core product, PROVENGE, is the first and only FDA-approved cellular immunotherapy for prostate cancer. Sanpower plans to promote PROVENGE's penetration outside of the US, starting with China and Southeast Asia.
In recent years Sanpower Group has determined the direction for Healthcare sector's growth, including health care, home care, genetic testing, precision medical and other fields. In fact, Sanpower Group previously acquired AnKangTong, Natali, and A.S. Nursing Company. In 2016, the group announced the acquisition of China Cord Blood Corporation and Shandong Cord Blood Bank, this means that it has emerged as the world's largest cord blood banking operator. The group also owns many medical and health institutions.
Agenda:
Time: 2 - 5 PM, April 22, 2018
2:00 - 2:05 PM: Introduction of CABS, Qiang Gan, Co-Chair of ICC, CABS
2:05 - 2:30 PM: Introduction of Sanpower Healthcare, Philip Bu, Senior VP, Sanpower Group
2:30 - 3:00 PM: Dendreon - Deal Sharing and Future Perspectives, Grace Xu, Chairperson, Dendreon; Senior Vice President, Sanpower Group
Speaker Biographies
Philip Bu
Mr. Phillip Bu is a Senior Vice President of Sanpower Group, concurrently serving as the Board Director of Cenbest(SH,600682),Chairman of the Biomedicine Industry Group and the Health & Senior Care Industry Group. Among other domestic and overseas companies, of which Mr. Bu is in charge, he overseas business, in relation to genetic testing, cell immunotherapy, hospital management and senior care, at Dendreon, Natali, Ankang Tong and More Health, Mecox Lane, Findgene as well as Xuzhou Third People's Hospital. Mr. Bu led many mergers and acquisitions to successfully conclusions at home and abroad. Further, he has spearheaded capital withdrawals from the Chinese securities market.
Grace Xu
As Dendreon Chairman, and Sanpower Group’s Senior Vice President, Ms XU is responsible for setting corporate strategy for the Healthcare sector, and prioritizing future M&A focus. Ms. Xu has 25 years of experience in the Pharmaceutical and Biotech industry, has served a number of global leading companies, Novartis, AstraZeneca, and BMS. She has capabilities and experiences in general management, corporate strategy planning, business development, M&A, and new product planning. She also has extensive international experience, in US, Europe, Middle East and Asia. Ms Xu has a MBA from Rotterdam school of management and a MS from University of Connecticut.
Han Ying, PhD
Dr. Ying has over 25 years pharmaceutical experience in oncology drug R&D, regulatory submission, clinical studies, and in starting and building biotech start-ups. He received his PhD at Stanford University in Cancer Biology Program, completed his post-doctoral training with Drs. Nicholas Restifo and Steven Rosenberg at the US National Cancer Institute. He became a principal investigator at Maxine Dunitz Neurosurgical Institute (affiliated with UCLA), where he oversaw a clinical laboratory conducting Dendritic Cell Vaccine trials for malignant brain tumor. He joined Berlex Biosciences (R&D arm of Schering A.G.) as a project leader in cancer research department, then joined Monogram Biosciences, a personalized medicine company that developed biomarkers for selection of patients for novel targeted drugs. In 2010, Dr. Ying co-founded Immunnova, a biotech company focused on dendritic cell vaccines and antigen-specific T cells. He was awarded grand champion in a national entrepreneurs contest in China. He has consulted for several early or late-stage biotech companies in the field of cancer immunotherapy, including HRYZ (Dendritic cell vaccines) and Sanpower Group/Dendreon. He was the key technical expert in an international M&A team that completed the acquisition of Dendreon by Sanpower group (0.9 billion dollars), acquisition of China Life Science Hong Kong facility. He received Advanced Certificate in Regulatory Affairs USFDA in 2007.
.